新冠疫苗接种与痛风发作风险在发作不频繁或频繁患者中的前瞻性队列研究
这项前瞻性队列研究纳入530例接受降尿酸治疗的痛风患者,按基线发作频率分为不频繁组(≤1次/年,308例)和频繁组(≥2次/年,222例),其中248例接种两剂新冠疫苗。接种疫苗仅在不频繁发作组增加12周累积发作率(26.1% vs 10.8%,P=0.001),频繁发作组无显著差异(60.4% vs 65.5%,P=0.428)。
要点
- 不频繁发作组接种疫苗后12周累积痛风发作率26.1%,未接种组10.8%(P=0.001)。
- 频繁发作组接种与未接种的12周累积发作率分别为60.4%和65.5%(P=0.428)。
- 不频繁发作组中疫苗接种与痛风发作风险独立相关(OR 2.82,95%CI 1.50-5.30,P=0.001)。
核心结论
- 新冠疫苗接种与既往发作不频繁的痛风患者早期痛风发作增加相关,而与频繁发作患者无此关联。
研究设计与样本
- 前瞻性队列研究,纳入2021年2月至6月接受降尿酸治疗且未接种新冠疫苗的痛风患者530例,按基线发作频率分为不频繁组(≤1次/年,308例)和频繁组(≥2次/年,222例),患者自愿决定是否接种疫苗,随访至入组或首剂疫苗接种后12周。
主要发现
- 不频繁发作组接种疫苗者12周累积痛风发作率为26.1%,未接种者为10.8%(P=0.001)。
- 频繁发作组接种疫苗者12周累积痛风发作率为60.4%,未接种者为65.5%(P=0.428)。
- 观察最后4周痛风发作率仅在不频繁发作组接种疫苗者中显著下降(4.3% vs 12.0%,P=0.017)。
- 不频繁发作组中,疫苗接种(OR 2.82,95%CI 1.50-5.30,P=0.001)、前一年痛风发作(OR 1.95,95%CI 1.03-3.71,P=0.04)和体重指数(OR 1.09,95%CI 1.01-1.19,P=0.03)与痛风发作风险增加独立相关。
- 频繁发作组中,基线血清尿酸(mg/dl)为独立危险因素(OR 1.23,95%CI 1.05-1.45,P=0.012)。
关键数值与推荐
- 不频繁发作组定义为≤1次痛风发作/年,频繁发作组定义为≥2次痛风发作/年。
- 主要比较指标为入组或首剂疫苗接种后12周累积痛风发作率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess post-COVID-19 vaccination gout flare risk with differing baseline flare burden. METHODS: We prospectively studied gout patients with infrequent or frequent flares, defined as ≤1 flare/year or ≥2 flares/year, respectively. COVID-19 vaccine-naive patients managed with urate-lowering therapy between February and June 2021 were included and voluntarily decided on vaccination. Participants were followed for 12 weeks after enrollment or first vaccine dose. Gout flares and risk factors were compared between groups. RESULTS: Of 530 participants, 308 (58.1%) had infrequent flares and 222 (41.9%) had frequent flares at baseline, with 248 (142 infrequent and 106 frequent) receiving two-dose COVID-19 vaccination. Vaccination increased cumulative flare incidence at 12 weeks in the infrequent but not the frequent flare group (26.1% vs 10.8%, P = 0.001, compared with 60.4% vs 65.5%, P = 0.428). Flare incidence in the final 4 weeks of observation decreased significantly only in the vaccinated infrequent flare group (4.3% vs 12.0%, P = 0.017). Multivariable analyses showed that vaccination (odds ratio [OR] 2.82, 95% confidence interval [95% CI] 1.50-5.30, P = 0.001), flare in the preceding year (OR 1.95, 95% CI 1.03-3.71, P = 0.04), and body mass index (OR 1.09, 95% CI 1.01-1.19, P = 0.03) were independently associated with increased flare risk in the infrequent flare group. Baseline serum urate (mg/dl) was an independent risk factor in the frequent flare group (OR 1.23, 95% CI 1.05-1.45, P = 0.012). CONCLUSION: COVID-19 vaccination was associated with increased early gout flares only in patients with previously infrequent flares.
引用
- He Y, Xue X, Dalbeth N, et al. COVID-19 Vaccination and Gout Flare Risk in Patients With Infrequent or Frequent Flares: A Prospective Cohort Study. Arthritis Care Res (Hoboken). 2023. PMID: 37553607. doi:10.1002/acr.25215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。